Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2018; 24(35): 3965-3973
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.3965
Role of endoscopic therapy in early esophageal cancer
Sonika Malik, Gautam Sharma, Madhusudhan R Sanaka, Prashanthi N Thota
Sonika Malik, Department of Internal Medicine, Cleveland Clinic Akron General Medical Center, Akron, OH 44307, United States
Gautam Sharma, Department of Anesthesiology, University Hospitals, Cleveland, OH 44106, United States
Madhusudhan R Sanaka, Prashanthi N Thota, Department of Gastroenterology, Digestive Disease Surgery Institute, Cleveland Clinic, OH 44195, United States
Author contributions: All authors contributed to the conception and design, acquisition of data and drafting of manuscript; all authors approved the final version of the article, including the authorship list.
Conflict-of-interest statement: Authors deny any conflict-of-interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Prashanthi N Thota, MD, FACG, Medical Director, Esophageal Center, Digestive Disease and Surgery Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States. thotap@ccf.org
Telephone: +1-216-4440780 Fax: +1-216-4454222
Received: July 9, 2018
Peer-review started: July 9, 2018
First decision: July 17, 2018
Revised: July 23, 2018
Accepted: August 1, 2018
Article in press: August 1, 2018
Published online: September 21, 2018
Core Tip

Core tip: Endoscopic eradication therapy (EET) plays a pivotal role in the management of patients with early esophageal cancer who are at very low risk for lymph node metastases. The main advantage of EET over surgery is the lower morbidity and mortality rates with similar cure rates, five-year survival rates and better quality of life. These excellent outcomes are tempered by the need for multiple treatment sessions for complete eradication and risk of post eradication recurrences. Careful patient selection by a multidisciplinary approach and patient compliance are crucial for treatment success.